These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 377697)

  • 41. Erythropoietin increases survival and attenuates fulminant hepatic failure injury induced by D-galactosamine/lipopolysaccharide in mice.
    Ben-Ari Z; Zilbermints V; Pappo O; Avlas O; Sharon E; Greif F; Cheporko Y; Ravid A; Shapiro R; Hochhauser E
    Transplantation; 2011 Jul; 92(1):18-24. PubMed ID: 21516061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An animal model of fulminant hepatic failure in the rat.
    Watanabe A; Higashi T; Nagashima H
    Acta Med Okayama; 1979 Dec; 33(6):443-50. PubMed ID: 161469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of calcium in liver cell damage. Comparative studies with carbon tetrachloride and D-galactosamine.
    Kröner H; Planker M
    Pathol Res Pract; 1980 Nov; 169(3-4):298-303. PubMed ID: 6261229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Homologous plasma cross-circulation on galactosamine induced hepatic failure rats].
    Ouchi K; Koyama K; Asanuma Y; Okabe K; Sato T
    Nihon Geka Gakkai Zasshi; 1984 May; 85(5):452-6. PubMed ID: 6749113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experimental galactosamine-induced hepatitis. Effect of anticoagulant and antifibrinolytic agents on microclot formation.
    Müller-Berghaus G; Reuter C; Bleyl U
    Am J Pathol; 1976 Feb; 82(2):393-406. PubMed ID: 1251892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FK 506 modulates D-galactosamine-induced hepatitis in rats.
    Farghali H; Gasbarrini A; Borle AB; Nalesnik MA; Francavilla A; Fagiuoli S; Starzl TE; Van Thiel DH
    Transplant Proc; 1991 Dec; 23(6):2809-11. PubMed ID: 1721285
    [No Abstract]   [Full Text] [Related]  

  • 47. [The anti-hepatotoxic effect of parenterally administered silymarin in galactosamine hepatitis of the rat].
    Schriewer H; Rausen HM
    Arzneimittelforschung; 1973 Jan; 23():Suppl:159. PubMed ID: 4740687
    [No Abstract]   [Full Text] [Related]  

  • 48. [Relation of serum glutathione S-transferase activity and pathologic abnormalities of the liver].
    Hu DR; Xie J; Li MD
    Zhonghua Nei Ke Za Zhi; 1988 May; 27(5):269-71, 325. PubMed ID: 3197493
    [No Abstract]   [Full Text] [Related]  

  • 49. [Studies on the rat model of surgically evoked acute liver failure].
    Zhang YX
    Zhonghua Yi Xue Za Zhi; 1989 Feb; 69(2):95-9. PubMed ID: 2670105
    [No Abstract]   [Full Text] [Related]  

  • 50. Hepatotoxic effect of D-galactosamine and protective role of lipid emulsion.
    Ferencíková R; Cervinková Z; Drahota Z
    Physiol Res; 2003; 52(1):73-8. PubMed ID: 12625810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transplantation of hepatocytes for treatment of surgically induced acute hepatic failure in the rat.
    Minato M; Houssin D; Demma I; Morin J; Gigou M; Szekely AM; Bismuth H
    Eur Surg Res; 1984; 16(3):162-9. PubMed ID: 6373295
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatoprotective effects of erythropoietin on D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice.
    Yang XF; He Y; Li HY; Liu X; Chen H; Liu JB; Ji WJ; Wang B; Chen LN
    Mol Med Rep; 2014 Jul; 10(1):555-9. PubMed ID: 24788561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison between the morphologic changes in the livers of hamsters and rats after galactosamine treatment and their correlation with altered serum transaminase levels.
    Pickering RW
    Arzneimittelforschung; 1977; 27(9):1684-7. PubMed ID: 579138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pattern of D-galactosamine-induced hepatocellular injury modified by simultaneous application of D (--)-fructose.
    Rumpelt HJ; Bode C
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1981; 36(2-3):235-45. PubMed ID: 6116337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A new hybrid artificial liver using a combination of hepatocytes and biomatrix.
    Saito S; Sakagami K; Orita K
    ASAIO Trans; 1987; 33(3):459-62. PubMed ID: 3314933
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of endotoxemia in galactosamine hepatitis by lactulose administered intravenously.
    Liehr H; Heine WD
    Hepatogastroenterology; 1981 Dec; 28(6):296-8. PubMed ID: 7345010
    [No Abstract]   [Full Text] [Related]  

  • 57. [Substance-induced liver injury as a model for evaluating hepatoprotective drugs].
    Trcka V; Siblíková O
    Cas Lek Cesk; 1985 Feb; 124(6):161-4. PubMed ID: 3971402
    [No Abstract]   [Full Text] [Related]  

  • 58. ["Galactosamine refractory" regenerating liver--a model for studies on the etiology mechanism of galactosamine hepatitis].
    Reutter W; Bauer C; Bachmann W; Lesch R
    Hoppe Seylers Z Physiol Chem; 1972 May; 353(5):747. PubMed ID: 5069316
    [No Abstract]   [Full Text] [Related]  

  • 59. [Effect of putrescine on experimental acute hepatic injury in rats].
    Wu XM; Zhang BG; Zhou Q; Li BR
    Yao Xue Xue Bao; 1988 Mar; 23(3):161-7. PubMed ID: 3421104
    [No Abstract]   [Full Text] [Related]  

  • 60. [(Blood coagulation disturbances of rats after acute liver damage produced by D-galactosamin-HCl) (author's transl)].
    Köstering H; Riesenkampff WG; Guerrero MA; Kositzki H
    Z Gastroenterol; 1977 Aug; 15(8):512-27. PubMed ID: 906601
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.